Diarrhea News and Research

Latest Diarrhea News and Research

New in vitro study results show that wound dressing with ionic silver kills strains of highly-resistant bacteria

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of highly-resistant bacteria, commonly referred to as 'superbugs.'

16 Apr 2011

Novocure's NovoTTF-100A System receives FDA approval for GBM treatment

Novocure today announced that the U.S. Food and Drug Administration approved the NovoTTF-100A System for the treatment of adult patients with glioblastoma multiforme brain tumors, following tumor recurrence after receiving chemotherapy.

16 Apr 2011

Genentech receives FDA approval for Actemra to treat juvenile idiopathic arthritis

The U.S. Food and Drug Administration today approved Actemra, given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis in children ages 2 years and older.

15 Apr 2011

Takeda announces EDARBI availability in U.S. pharmacies for hypertension treatment

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that EDARBI, an angiotensin II receptor blocker approved for the treatment of hypertension, or high blood pressure, is now available by prescription for adults in U.S. pharmacies.

15 Apr 2011

Consumer group calls for ban on weight loss drugs Alli and Xenical

According to the consumer watchdog Public Citizen, the weight loss drugs Alli and Xenical should be removed from the market because of the growing risk of side effects that include liver damage, pancreatitis and kidney stones.

15 Apr 2011

Ortho-McNeil Neurologics announces voluntary recall of TOPAMAX 100mg Tablets

Ortho-McNeil Neurologics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., today announced it is voluntarily recalling two lots of TOPAMAX® (topiramate) 100mg Tablets. These two lots were shipped between 10/19/2010 and 12/28/2010 and distributed in the U.S. and Puerto Rico.

15 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

Cepheid receives FDA clearance for new assay to detect C. difficile infection

The U.S. Food and Drug Administration today cleared a test called the Cepheid Xpert C. difficile/Epi assay that is designed to rapidly detect the toxin B gene associated with Clostridium difficile infection, a cause of diarrhea that can lead to colitis, other serious intestinal conditions and death in severe cases.

11 Apr 2011

AJG publishes new review on Inflammatory Bowel Disease management

The American College of Gastroenterology published a new evidence-based systematic review on the management of Inflammatory Bowel Disease as a supplement to The American Journal of Gastroenterology for April 2011, a special issue entirely dedicated to IBD.

8 Apr 2011

Shionogi launches CUVPOSA for pediatric chronic severe drooling

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.

7 Apr 2011

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

7 Apr 2011

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.

7 Apr 2011

Lupin grants Salix exclusive worldwide rights to rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of March 31, 2011 Lupin Ltd. granted Salix exclusive worldwide rights (except for India) to exploit Lupin technology and technology jointly developed by Lupin and Salix for all rifaximin products for human use. This agreement expands the collaboration that Salix and Lupin entered into as of September 30, 2009.

6 Apr 2011

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Optimer Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID, in the United States.

6 Apr 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.

6 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

Cubist Pharmaceuticals, Inc. today announced that it has entered into a license agreement with Teva Parenteral Medicines, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., which includes a stipulation by the parties requesting dismissal of the lawsuit filed by Cubist in the U.S. District Court for the District of Delaware relating to the Abbreviated New Drug Application filed by TPM with the U.S. Food and Drug Administration for a generic version of CUBICIN.

5 Apr 2011

South Asian Conference on Sanitation kicks off in Sri Lanka

The fourth South Asian Conference on Sanitation kicked off Monday in the Sri Lankan capital city of Colombo, to raise awareness about the "sanitation crisis in the region," Xinhua reports.

5 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011